И за воља на вистината, вчера гледав студија, за вакцинирани не прележани и вакцинирани со една доза прележани.
Практично тие што се прележани и вакцинирани имаат огромна предност на 13 месеци.
From Month 7, anti-RBD antibodies stabilize at a level that neutralizes infectious variants D614G and B.1.1.7, but less B.1.351, suggesting that most COVID-19 positive patients may be protected from reinfection by the former variants. [This study also shows the level of anti-RBD IgG titers was reached by all vaccinated person's regardless of pre-vaccination IgG levels and type of vaccine]
The incidence of SARS-CoV-2 infections was 12.22 and 0.40 per 100 person-years in COVID-19-negative and COVID-19-positive HCW, respectively, indicating a relative reduction in the incidence of SARS-CoV-2 reinfection of 96.7%. [during 1 year timeslice there were 69 infections amongst the 916 negative HCW, and one asymptomatic reinfection amongst the 393 previously positive]
69 од 916 заболеле од корона, за разлика од тие што биле прележани каде само 1 од 393 бил позитивен асимптоматски.
Our study demonstrates a long-term persistence of anti-RBD antibodies that may reduce risk of reinfection. By significantly increasing cross-neutralizing antibody titers, a single-dose vaccination strengthens protection against variants.
www.thelancet.com
Реално прележаните мислам дека ќе ги имале истите резултати и да не биле вакцинирани.